Granules India (532482) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 was impacted by a voluntary production pause at the Gagillapur facility after a US FDA inspection resulted in six Form 483 observations and an OAI classification; operations resumed in October with 90% of CAPAs completed and closure expected by March 2025.

• Leadership was strengthened with new appointments in quality and manufacturing; OAI status does not impact ongoing sales but delays new product approvals from the site.

• New product launches and approvals included Lisdexamfetamine and Trazodone Hydrochloride in the US, with expansion into CNS, oncology, and anti-diabetic areas.

• Growth strategy is driven by new launches from the US GPI facility, expansion in Europe, and a new greenfield formulation facility at Genome Valley.

• Consolidated revenue for Q3 FY25 was Rs 11,376.95 million, down year-over-year.

Financial highlights

• Q3 FY25 revenue was INR 11,377 million, down 2% year-over-year but up 18% sequentially from Q2 FY25.

• Gross margin improved to 61.7% from 57% year-over-year; EBITDA for Q3 FY25 was INR 2,303 million (20.2% margin), down from INR 2,505 million (21.7%) year-over-year.

• PAT for Q3 FY25 was Rs. 1,176 million, a 6% decrease year-over-year but a 21% increase sequentially.

• R&D spend for the quarter was INR 568 million, up from INR 468 million year-over-year.

• Net debt stood at INR 8,289 million, with a cash-to-cash cycle of 213 days and DSO at 76 days.

• CapEx for the quarter was INR 1,335 million, mainly for Granules Life Sciences.

• ROC for Q3 FY25 was 16.4%.

• Cash flow from operations for Q3 FY25 was INR 1,315 million.

Outlook and guidance

• Long-term revenue CAGR expected to remain above 20%, with FY26 projected to see around 20% growth aided by new capacity and product launches.

• EBITDA margin guidance in the 20–22% range, with gross margins expected to improve as one-off costs subside.

• Near-term growth to be driven by new launches from the GPI site and commercialization from the Genome Valley facility.

• Some new product launches delayed due to OAI status, but four to five launches from GPI will proceed as planned.

• Continued R&D investments and higher regulatory expenses may impact margins in the near term.